Cell production rates in human tissues and tumours and their significance. Part II: clinical data

European Journal of Surgical Oncology

Volumn 26, Issue 4, 2000, Pages 405-417

  Rew, D A ^a   Wilson, G D ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b Group for Biostatistics in Oncology   (United Kingdom)

Author keywords

Bromodeoxyuridine; Cancer; Cell proliferation; Clinical outcome; Flow cytometry; Iododeoxyuridine; Prognosis

Indexed keywords

PYRIMIDINE;

CELL CYCLE S PHASE; CELL LOSS; CELL PROLIFERATION; CYTOMETRY; DNA SYNTHESIS; PRIORITY JOURNAL; REVIEW; TISSUE GROWTH; TUMOR;

EID: 0033940198     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1999.0907     Document Type: Review

References (94)

1. Rew DA, Wilson GD. Cell proliferation rates in human tissues and tumours: Part I. Eur J Surg Oncol. 26:2000.
2. Dolbeare F. Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part I: Historical perspectives, histochemical methods and cell kinetics [Review]. Histochem J. 27:1995;339-369.
3. Dolbeare F. Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis. Histochem J. 27:1995;923-964.
4. Forster G, Cooke TG, Cooke LD, Stanton PD, Bowie G, Stell PM. Tumour growth rates in squamous carcinoma of the head and neck measured by in vivo bromodeoxyuridine. Br J Cancer. 65:1992;698-702.
5. Jones AS, Roland NJ, Caslin AW, Cooke TG, Cooke LD, Forster G. A comparison of cellular proliferation markers in squamous cell carcinoma of the head and neck. J Laryngol Otol. 108:1994;859-864.
6. Nylander K, Anneroth G, Gustafsson H, Roos G, Stenling R, Zackrisson B. Cell kinetics of head and neck squamous cell carcinomas. Prognostic implications. Acta Oncol. 33:1994;23-28.
7. Bennett MH, Wilson GD, Dische S, Saunders MI, Martindale CA, Robinson BM, O'Halloran AE, Leslie MD, Laing JH. Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer. 65:1992;870-878.
8. Marchal S, Marchal C, Parache RM, Benjaafar N, Odda M, Leclerc A, Merlin J-L, El Gueddarri B, Bey P. Combined flow cytometry and immunohistochemistry analyses for the assessment of nasopharyngeal carcinoma cell kineticsin vivo by bromodeoxyuridine infusion. Cytometry. 29:1997;165-172.
9. Hoyer M, Jorgensen K, Bundegaard T, Johansen LV, Bentzen SM, Overgaard M, Hansen O, Sogaard H, Overgaard J. Lack of predictive value of potential doubling time and iodeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology. 46:1998;147-155.
10. Benazzo M, Mevio E, Occhini A, Franchini G, Danova M. Proliferative characteristics of head and neck tumours. In vivo evaluation by BrdUrd incorporation and flow cytometry Orl. J Oto-Rhino-Laryngol. 57:1995;39-43.
11. Kotelnikov VM, Coon JS, Taylor S, Hutchinson J, Panje W, Caldarelli DD, LaFollette S, Preisler HD. In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region. Cell Proliferation. 28:1995;497-509.
12. Kotelnikov VM, Coon JS, Haleem A, Taylor S, Hutchinson J, Panje W, Caldarelli DD, Griem K, Preisler HD. Cell kinetics of head and neck cancers. Clin Cancer Res. 1:1995;527-537.
13. Kotelnikov VM, Coon JS, Mundle S, Kelanic S, LaFollette S, Taylor IVS, Hutchinson J, Panje W, Caldarelli DD, Preisler HD. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clinical Cancer Res. 3:1997;95-101.
14. Cooke LD, Cooke TG, Forster G, Jones AS, Stell PM. Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival. Br J Cancer. 69:1994;717-720.
15. Kakinuma K, Tanaka R, Onda K, Takahashi H. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BrdUrd and Ki-67, and tumour doubling time. Acta Neurochirurgica. 140:1998;26-32.
16. Riccardi A, Danova M, Wilson GD, Ucci G, Dormer P, Mazzini G, Brugnatelli S, Girino M, McNally N, Ascari E. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res. 48:1988;6238-6245.
17. Danova M, Gaetani P, Lombardi D, Giordano M, Riccardi A, Mazzini G. Prognostic value of DNA ploidy and proliferative activity in human malignant gliomas. Med Sci Res. 19:1991;613-615.
18. Shibuya M, Ito S, Davis RL, Wilson C, Hoshino T. A new method for analyzing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro. Cancer. 71:1993;3109-3113.
19. Scruikmans H, Rutgers DH, Jansen GH, Tulleken CAF, Van der Tweel I, Batterman JJ. S phase fraction, bromodeoxyuridine labelling index, duration of S phase, potential doubling time and DNA index in benign and malignant brain tumours. Radiation Oncol Investigations. 5:1997;170-179.
20. Struikmans H, Rutgers DH, Jansen GH, Tulleken CAF, Van der Tweel I, Batterman JJ. Prognostic relevance of cell proliferation markers and DNA ploidy in gliomas. Acta Neurochirurgica. 140:1998;140-147.
21. Wilson GD. Assessment of human tumour proliferation using bromodeoxyuridine - current status. Acta Oncologica. 30:1991;903-910.
22. Rew DA. The in vivo proliferation kinetics of human solid tumors. MChir Thesis, University of Cambridge, UK. 1991.
23. Haustermans K, Vanuytsel L, Geboes K, Lerut T, Van Thillo J, Leysen J, Coosemans W, van der Schueren E. In vivo cell kinetic measurements in human oesophageal cancer: what can be learned from multiple biopsies? Eur J Cancer. 30A:1994;187-191.
24. Haustermans K, Fowler F, Geboes K, Lerut T, van der Schueren E. Do cell kinetics have prognostic and/or predictive value in oesophageal cancer treated by surgery? Eur J Surg Oncol. 23:1997;293-297.
25. Haustermans K. In vivo growth kinetic measurements in human oesophageal cancer. PhD Thesis, University of Leiden, Holland. 1995.
26. Miwa H, Wada R, Abe H, Ohkura R, Yang SW, Watanabe H, Ogihara T, Hamada T, Sato N. Diagnosis of gastric adenoma versus early gastric cancer by bromodeoxyuridine immunohistochemistry from gastric biopsy specimen. J Gastroenterol Hepatol. 8:1993;133-137.
27. Ohyama S, Yonemura Y, Miyazaki I. Prognostic value of S phase fraction and DNA ploidy studied with in vivo administration of bromodeoxyuridine on human gastric cancers. Cancer. 65:1990;116-121.
28. Rew DA. Cell proliferation, tumor growth and clinical outcome: gains and losses in intestinal cancer. Ann R Coll Surg Engl. 75:1993;397-404.
29. Camplejohn RS. Cell kinetics of colorectal tumours. Recent Results Cancer Res. 83:1982;21-30.
30. Risio M, Coverlizza S, Ferrari A, Candelaresi GL, Rossini FP. Immunohistochemical study of epithelial cell proliferation in hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. Gastroenterology. 94:1988;899-906.
31. Khan S, Raza A, Petrelli N, Mittleman A. In vivo determinations of labelling index of metastatic colorectal carcinoma and normal colonic mucosa using intravenous infusions of bromodeoxyuridine. J Surg Oncol. 39:1988;114-118.
32. Rew DA, Wilson GD, Taylor I, Weaver PC. Proliferation characteristics of 100 colorectal tumours measured in vivo. Br J Surg. 78:1991;60-66.
33. Wilson MS, West CM, Wilson GD, Roberts SA, James RD, Schofield PF. An assessment of the reliability and reproducibility of measurement of potential doubling times in human colorectal cancers. Br J Cancer. 67:1993;754-759.
34. Terry NH, Meistrich ML, Roubein LD, Lynch PM, Dubrow RA, Rich TA. Cellular kinetics in rectal cancer. Br J Cancer. 72:1995;435-441.
35. Palmqvist R, Oberg A, Bergstrom C, Rutegard JN, Zackrisson B, Stenling R. Systematic heterogeneity and prognostic significance of cell proliferation in colorectal cancer. Br J Cancer. 77:1998;917-925.
36. Bergstrom C, Palmqvist R, Denekamp J, Oberg A, Tavelin B, Stenling R. Factors influencing the estimates of proliferative labelling indices in rectal cancer. Radiother Oncol. 46:1998;169-177.
37. Michel P, Hermet J, Paresy M, Menard JF, Laquerriere A, Scotte M., Comparison between endoscopic and surgical sampling for the measurement of potential doubling time in colorectal cancer. Cytometry. 29:1997;273-278.
38. Wilson MS, West CM, Wilson GD, Roberts SA, James RD, Schofield PF. Intratumoral heterogeneity of tumor potential doubling times in colorectal cancers. Br J Cancer. 68:1993;501-506.
39. Bergstrom C, Stenling R. Proliferative heterogeneity in colorectal cancer, studied using iododeoxyuridine. Abstract to European Study Group for cell proliferation. ESPOO XVII, Finland. Sept 1990.
40. Rew DA, Taylor I, Watson JV, Wilson GD. The c-myc protein product is a marker of DNA synthesis but not of malignancy in gastrointestinal tissues and tumours. Br J Surg. 78:1991;1080-1083.
41. Rew DA, Karkera R, Stradling R, Mullee M, Julious S, Wilson GD. The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome. Eur J Surg Oncol. 22 5:1996;508-515.
42. Goodson WH, Moore DH, Ljung B-M, Chew K, Florendo C, Mayall B, Smith HS, Waldman FM. The functional relationship between in vivo BrdUrd labelling index and Ki-67 proliferation index in human breast cancer. Breast Cancer Research and Treatment. 49:1998;155-164.
43. Rew DA, Campbell I, Taylor I, Wilson GD. The in vivo proliferation kinetics of invasive carcinoma of the breast. Br J Surg. 79:1992;335-339.
44. Ashton-Key M, Coddington R, Rew DA, Campbell ID, Taylor I. Quantitative indices of proliferation using bromodeoxyuridine: A study of sixty invasive breast carcinomas. The Breast. 2:1993;42-47.
45. Stanton PD, Cooke TG, Forster G, Smith D, Going JJ. Cell kinetics in vivo of human breast cancer. Br J Surg. 83:1996;98-102.
46. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD. Quantitative estimation of epidermal growth factor receptor and c-erbB2 in human breast cancer. Cancer Res. 56:1996;3823-3830.
47. Erba E, Giordano M, Danova M, Mazzini G, Ubezio P, Torri V, Mangioni C, Landoni F, Bolis P, Tenti P., Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine. Annals Oncol. 5:1994;627-634.
48. Bolger BS, Cooke TG, Symonds RP, MacLean AB, Stanton PD. Measurement of cell kinetics in cervical tumors using bromodeoxyuridine. Br J Cancer. 68:1993;166-171.
49. Bolger BS, Cooke TG, Symonds RP, MacLean AB, Stanton PD. Prediction of radio-therapy response of cervical tumors through measurement of proliferation rate. Br J Cancer. 74:1996;1223-1226.
50. Tsang RW, Fyles AW, Kirkbride P, Levin W, Manchul LA, Milosevic MF, Rawlings GA, Banerjee D, Pintilie M, Wilson GD. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys. 32:1995;1319-1329.
51. Laing JHE, Rew DA, Wilson GD. Cell kinetics of human solid tumours. Br J Radiol. Suppl 24:1992;163-167.
52. Raza A, Ucar K, Preisler HD. Double labelling and in vitro versus in vivo incorporation of BrdUrd in patients with acute nonlymphocytic leukemia. Cytometry. 6, 6:1985;633-641.
53. Raza A, Yousuf N, Bokhari SA. In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdUrd. Leuk Res. 16:1992;299-306.
54. Raza A, Alvi S, Broady-Robinson L, Showel M, Cartlidge J, Mundle SD, Gregory SA., Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Experimental Hematology. 25:1997;530-535.
55. Giordano M, Danova M, Mazzini G, Gobbi P, Riccardi A. Cell kinetics with in vivo bromodeoxyridine assay, proliferating cell nuclear antigen expression, and flow cytometric analysis. Prognostic significance in acute non-lymphoblastic leukemia. Cancer. 71:1993;2739-2745.
56. Wilson GD. HP Beck-Bornholdt (ed). Medical Radiology, Current Topics in Clinical Radiobiology of Tumours. Berlin: Springer Verlag. 1993.
57. Tinnemans MM, Schutte B, Lenders MH, Ten Velde GP, Ramaekers FC, Blijham GH. Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling. Br J Cancer. 67:1993;1217-1222.
58. Nemoto R, Hattori K, Sasaki A, Miyanaga N, Koiso K, Harada M. Estimations of the S phase fraction in situ in transitional cell carcinoma of the renal pelvis and ureter with bromodeoxyuridine labeling. Br J Urol. 64:1989;339-344.
59. Nemoto R, Uchida K, Hattori K, Shimazui T, Nishijima Y, Saito S, Koiso K, Harada M. S phase fraction of human bladder tumor measured in situ with bromodeoxyuridine labeling. J Urol. 139:1988;286-289.
60. Nemoto R, Uchida K, Hattori K, Shimazui T, Koiso K, Harada M. Immunochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma. J Urol. 141:1989;337-340.
61. Tachibana M, Miyakawa A, Nakamura K, Baba S, Murai M, Tazaki H. Role of proliferative activity estimated by BrdUrd labeling index in determining predictive factors of recurrence in superficial intermediately malignant bladder tumors. J Urol. 156:1996;63-69.
62. Ota T, Akaza H, Hattori K, Uchida K. The relationship between the estimated tumour growth speed and indicees of BrdUrd incorporation and PCNA expression in superficial bladder cancer. Japn J Urol. 88:1997;868-873.
63. Larsson P, Roos G, Stenling R, Wilson GD, Ljungberg B. Cell proliferation in renal cell carcinoma - a comparative study of cell kinetic methods. Urol Research. 24:1996;281-285.
64. Rew DA, Thomas DJ, Coptcoat MJ, Wilson GD. In vivo measurement of urothelial tumor kinetics. Br J Urol. 68:1991;44-48.
65. Popert RJ, Joyce AD, Thomas DJ, Walmsley BH, Coptcoat MJ. BrdUrd labelling of transitional cell carcinoma of the bladder: an index of recurrence? Br J Urol. 71:1993;279-283.
66. Haustermans KMG, Hofland I, Van Poppel H, Oven R, Van de Voorde W, Begg AC, Fowler JF. Cell kinetic measurements in prostate cancer. Int J Radiat Biol Phys. 37:1997;1067-1070.
67. Wilson GD, Dische S, Saunders MI. Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiother Oncol. 36:1995;189-197.
68. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopultation during radiotherapy. Acta Oncol. 27:1988;131-146.
69. Dische S, Saunders MI. Continuous, hyperfractionated, accelerated radiotherapy (CHART). Br J Cancer. 59:1989;325-326.
70. Saunders MI, Dische S, Grosch E, Fermont DC, Ashford R, Maher J, Makepeace AR. Experience with CHART. Int J Radiat Oncol Biol Phys. 21:1991;871-878.
71. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S. BCL2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res. 16:1996;2403-2408.
72. Bourhis J, Wilson G, Wibault P, Chavaudra N, Janot F, Luboinski B, Eschwage F, Malaise EP. In vivo measurement of the potential doubling time by flow cytometry in oropharyngeal cancer treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys. 26:1993;793-799.
73. Corvo R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Barra S, Margarino G, Bacigalupo A, Vitale V. Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control. Int J Radiat Oncol Biol Phys. 27:1993;1165-1172.
74. Corvo R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M, Vitale V. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol. 13:1995;1843-1850.
75. Begg AC, Hofland I, Moonen L, Bartelink H, Schraub S, Bontempts P, Le Fir R, Van den Bogaert W, Caspers R, van Glabbeke M, Horiot J-C. The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys. 19:1990;1449-1453.
76. Begg AC, Hofland I, Van Glabbeke M, Bartelink H, Horiot J-C. Predictive value of potential doubling time for radiotherapy of hand and neck tumour patients: results from the EORTC cooperative trial 22851. Seminars in Radiat Oncol. 2:1992;22-25.
77. Bourhis J, Dendale R, Hill C, Bosq J, Janot F, Attal P, Fortin A, Marandas P, Schwaab G, Wibault P, Malaise EP, Bobin S, Luboinski B, Eschwege F, Wilson G. Potential doubling time and clinical outcome in head and neck squamous cell carcinomas treated with 70 GY in 7 weeks. Int J Radiat Oncol Biol Phys. 35:1996;471-476.
78. Antognoni P, Bignardi M, Cazzaniga LF, Poli AM, Richetti A, Bossi A, Rampello G, Barbera F, Soatti C, Bardelli D, Giordano M, Danova M. Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics - a phase II multicenter study. Int J Radiat Oncol Biol Phys. 36:1996;1137-1145.
79. Zackrisson B, Gustafsson H, Stenling R, Flygare P, Wilson GD. Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys. 38:1997;677-683.
80. Corvo R, Giaretti W, Geido E, Sanguineti G, Orecchia R, Scala M, Garaventa G, Mora E, Vitale V. Cell kinetics and tumor regression during radiotherapy in head and neck squamous cell carcinomas. Intl J Cancer. 68:1996;151-155.
81. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 44:1997;111-121.
82. Begg A, Haustermans K, Wilson GD. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicentre analysis. Radiother Oncol. 50:1999;13-23.
83. Dolbeare F. Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization. [Review]. Histochemical J. 28:1996;531-575.
84. Van Erp PE, Boezeman JB, Brons PP. Cell cycle kinetics in normal human skin by in vivo administration of iododeoxyuridine and application of a differentiation marker - implications for cell cycle kinetics in psoriatic skin. Analytical Cellular Pathology. 11:1996;43-54.
85. Patel S, Rew DA, Taylor I, Potten CS, Roberts S. Studies of proliferation in human gastric mucosa following in vivo bromodeoxyuridine labeling. Gut. 34, 7:1993;893-896.
86. Potten CS, Kellett M, Roberts S, Rew DA, Wilson GD. Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine. Gut. 33:1992;71-78.
87. Potten CS, Kellett M, Roberts S, Rew DA. Proliferation in human gastrointestinal epithelium using bromodeoxyuridine in vivo: data for different sites, proximity to a tumor, and polyposis coli. Gut. 33:1992;524-529.
88. Rew DA, Reeve L, Wilson GD. A comparison of flow and laser scanning cytometry for the assay of cell proliferation in human solid tumours. Cytometry. 33:1998;355-361.
89. Tannock I. Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol. 49:1986;335-355.
90. Van Putten LM. Cell Kinetics, a guide for chemotherapy? Controversies in Cancer. Masson Publishing. 1979;117-119.
91. Denekamp J. Cell kinetics and radiation biology. Int J Radiat Biol. 49, 2:1986;357-380.
92. Kummermehr J, Trott K-R. Rate of repopulation in a slow and fast growing mouse tumour. In Karcher KH et al. (eds). Progress in Radio-oncology II, New York: Raven Press. 1982;299-308.
93. Terry NHA. Predictive assays for radiotherapy: the role of tumour proliferation (Tpot) measurements. Onkologie. 19:1996;322-327.
94. Webster L, Hodgkiss RJ, Wilson GD. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br J Cancer. 77:1998;227-234.